PI 3-kinase, mTOR, protein synthesis and cancer

Class I PI3K in oncogenic cellular transformation.

Oncogene·2008

Constitutively active Rheb induces oncogenic transformation.

Oncogene·2008

Oncogenic signaling of class I PI3K isoforms.

Oncogene·2007

Phosphorylation by Akt disables the anti-oncogenic activity of YB-1.

Oncogene·2007

A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.

Oncogene·2007

Retroviral oncogenes and TOR.

Current topics in microbiology and immunology·2003

The niche-metabolism axis: reprogramming tumor-associated macrophages for precision immunotherapy.

Trends in molecular medicine·2026

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

Trends in molecular medicine·2026

Formicitoxins: membrane-targeting antifungal peptides from carpenter ant venoms.

Trends in molecular medicine·2026

Tumor metaboception: local PGE2 signals global decline.

Trends in molecular medicine·2026

Statins suppress colon tumors by inhibiting KRAS condensates.

Trends in molecular medicine·2026

RNA translational control in skeletal development, homeostasis, and disease.

Trends in molecular medicine·2026

Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

Folia histochemica et cytobiologica·2026

DPM2 promotes melanoma progression and serves as a prognostic factor.

Melanoma research·2026

Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

QJM : monthly journal of the Association of Physicians·2026

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Cancer discovery·2026

Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

RSC medicinal chemistry·2026

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Frontiers in medicine·2026

Related Experiment Videos

PI 3-kinase, mTOR, protein synthesis and cancer

Related Concept Videos

Class I PI3K in oncogenic cellular transformation.

Constitutively active Rheb induces oncogenic transformation.

Oncogenic signaling of class I PI3K isoforms.

Phosphorylation by Akt disables the anti-oncogenic activity of YB-1.

A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.

Retroviral oncogenes and TOR.

The niche-metabolism axis: reprogramming tumor-associated macrophages for precision immunotherapy.

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

Formicitoxins: membrane-targeting antifungal peptides from carpenter ant venoms.

Tumor metaboception: local PGE2 signals global decline.

Statins suppress colon tumors by inhibiting KRAS condensates.

RNA translational control in skeletal development, homeostasis, and disease.

Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

DPM2 promotes melanoma progression and serves as a prognostic factor.

Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Related Experiment Videos

PI 3-kinase, mTOR, protein synthesis and cancer

Related Concept Videos

Related Articles